<DOC>
	<DOCNO>NCT00778752</DOCNO>
	<brief_summary>This study Phase I ( non-randomized ) study evaluate three dose-levels Lenalidomide patient allogeneic stem cell transplantation , accomplish two institution ( University Medical Center Hamburg-Eppendorf/ University Medical Center Heidelberg ) .</brief_summary>
	<brief_title>Dose-finding Lenalidomide Maintenance Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Age &gt; 18 year time signing informed consent form Able adhere study visit schedule protocol requirement Multiple myeloma patient receive allogeneic stem cell transplantation ( 100 180 day ago ) No active acute GvHD ( grade II IV ) No active infectious complication ECOG performance status &lt; 2 study entry Laboratory test result within range : Absolute WBC count &gt; 3.0 x 10^9/l Platelet count &gt; 80 x 10^9/l Serum creatinine &lt; 1.5 mg/dl Total bilirubin &lt; 1,5 mg/dl AST ( SGOT ) ALT ( SGPT ) &lt; 3 x ULN Females childbearing potential must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse least 28 day start study drug , participate study least 28 day discontinuation study . male subject must agree use latex condom sexual contact female childbearing potential participate study least 28 day discontinuation study drug disease free prior malignancy &gt; 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form pregnant breast feeding female use experimental drug therapy within 28 day baseline know hypersensitivity thalidomide concurrent use anticancer agent treatment know positive HIV infectious hepatitis , type A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>